Business
IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference
New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE
About this update from Imunon, Inc.
[{"type":"text","content":"New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science Officer, presented new PlaCCine preclinical data at the 2023 Viruses and Cells – Gordon Research Conference in Barcelona. Dr. Khursheed’s presentation, titled “A Novel DNA Vaccine Approach to Prophylactic and Therapeutic Vaccines,” was delivered on May 25, 2023, and described IMUNON’S PlaCCine technology platform for the development of next-generation vaccines. Dr. Anwer’s presentation is available [here]. Results from preclinical studies in a PlaCCine COVID-19 vaccine demonstrated characteristics that address the limitations of current commercial vaccines by offering enhanced breadth of protection to emerging variants, persistence and robust cellular immunity, as well as stability at workable temperatures. Importantly, humoral immune responses specific to the SARS-CoV-2 spike antigen were persistent over a 14-month post-vaccination period in mice, while the T-cell responses from PlaCCine COVID-19 vaccines after 14 months were higher than a commercial mRNA vaccine. In another mouse study, the humoral response to a single dose of a commercial mRNA vaccine plateaued within 14 days after vaccination while the response continued to increase over time with a PlaCCine vaccine, demonstrating improved durability. In addition, PlaCCine was stable for at least eight months at refrigerated temperatures and for at least one month at room temperature. Dr. Corinne Le Goff, President and Chief Executive Officer of IMUNON, said, “These preclinical findings underscore the potential of our PlaCCine platform to produce next-generation COVID-19 vaccines that address the limitations of the current commercial products. We are delighted the data continue to show greater durability of response, which is vitally important as we experience vaccine fatigue in populations asked to be inoculated multiple times a year. In addition, our plug-and-play approach permitting the design and development of vaccines to new variants or targets within th...